One mechanism by which AML cells develop resistance to venetoclax is the upregulation of other anti-apoptotic proteins, including MCL-1, which can sequester BAX and BIM, thus compensating for the loss of BCL-2 function [11,17,18,19]. This evidence concerns the gene MCL1 and acute myeloid leukemia.